Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shenghui Tang

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> AlterationsAsma Dilawari, James Buturla, Christy Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinomaVicki L Goodman, Edwin P Rock, Ramzi Dagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
The Oncologist|October 5, 2020
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerShaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Sundeep Agrawal, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> AlterationsAsma Dilawari, James Buturla, Christy Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinomaVicki L Goodman, Edwin P Rock, Ramzi Dagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
The Oncologist|October 5, 2020
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerShaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Sundeep Agrawal, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Pageof 12